Mimetas is the market leader in Organ-on-a-Chip technology, based in The Netherlands, Maryland, US, and Tokyo, Japan.
Their flagship product, the OrganoPlate®, supports 3D cell culture under continuous perfusion. The OrganoPlate allows permeability, transport, migration/invasion, and co-culture assays without the use of filter membranes.
Mimetas works with the majority of pharma and biotech companies around the world. Their extensive R&D team has developed a broad spectrum of models and assays to advance drug development.
Financing round - Series B
Number of Employees